A Once-Daily Dasatinib Dosing Strategy for Chronic Myeloid Leukemia

Clinical Journal of Oncology Nursing

Volumn 13, Issue 3, 2009, Pages 316-323

  Bryant, George ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DASATINIB; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; CHRONIC MYELOID LEUKEMIA; DRUG ADMINISTRATION; DRUG INTERACTION; HUMAN; NURSING; PATIENT COMPLIANCE;

ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PATIENT COMPLIANCE; PYRIMIDINES; THIAZOLES;

EID: 69449090285     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/09.CJON.316-323     Document Type: Article

References (46)

1. Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., et al. (2003). Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood, 102(1), 276-283.
2. ® prescribing information. Retrieved May 6, 2008, from http://packageinserts.bms.com/pi/pi_sprycel.pdf
3. Claxton, A.J., Cramer, J., & Pierce, C. (2001). A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics, 23(8), 1296-1310.
4. Cortes, J., Rousselot, P., Kim, D.W., Ritchie, E., Hamerschlak, N., Coutre, S., et al. (2007). Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109(8), 3207-3213.
5. da Silveira, V.L., Drachler, M.L., Leite, J.C., & Pinheiro, C.A. (2003). Characteristics of HIV antiretroviral regimen and treatment adherence. Brazilian Journal of Infectious Diseases, 7(3), 194-201.
6. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., et al. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355(23), 2408-2417.
7. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., et al. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344(14), 1031-1037.
8. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., et al. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine, 2(5), 561-566.
9. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H.M. (1999). The biology of chronic myeloid leukemia. New England Journal of Medicine, 341(3), 164-172.
10. Gallant, J.E., & Block, D.S. (1998). Adherence to antiretroviral regimens in HIV-infected patients: Results of a survey among physicians and patients. Journal of the International Association of Physicians in AIDS Care, 4(5), 32-35.
11. Gambacorti, C., Cortes, J., Kim, D.W., Dombret, H., Zhu, C., Van Tornout, J.M.A., et al. (2007). Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program [Abstract 472]. Blood (ASH Annual Meeting Abstracts), 110(11).
12. Guilhot, F., Apperley, J., Kim, D.W., Bullorsky, E.O., Baccarani, M., Roboz, G.J., et al. (2007). Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 109(10), 4143-4150.
13. Guilhot, F., Apperley, J.F., Kim, D.W., Rosti, G., Yuan, X., Van Tornout, J.M.A., et al. (2007). Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005) [Abstract 470]. Blood (ASH Annual Meeting Abstracts), 110(11).
14. Hahn, E.A., Glendenning, G.A., Sorensen, M.V., Hudgens, S.A., Druker, B.J., Guilhot, F., et al. (2003). Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemiaon imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS Study. Journal of Clinical Oncology, 21(11), 2138-2146.
15. Hamdan, M.Y., Sanders, L., Oliveria, S., Campbell, U., Willey, V., Hirji, I., et al. (2007). Discontinuation and dose modification of imatinib in clinical practice. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings), 25(18S), 7045.
16. Hochhaus, A., Erben, P., Ernst, T., & Mueller, M.C. (2007). Resistance to targeted therapy in chronic myelogenous leukemia. Seminars in Hematology, 44(1, Suppl. 1), S15-S24.
17. Hochhaus, A., Kantarjian, H.M., Baccarani, M., Lipton, J.H., Apperley, J.F., Druker, B.J., et al. (2007). Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 109(6), 2303-2309.
18. Hu, Y., Swerdlow, S., Duffy, T.M., Weinmann, R., Lee, F.Y., & Li, S. (2006). Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proceedings of the National Academy of Sciences in the United States of America, 103(45), 16870-16875.
19. Hughes, T., & Branford, S. (2006). Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Reviews, 20(1), 29-41.
20. Jabbour, E., Cortes, J.E., Giles, F.J., O'Brien, S., & Kantarjian, H.M. (2007). Current and emerging treatment options in chronic myeloid leukemia. Cancer, 109(11), 2171-2181.
21. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M.J. (2007). Cancer statistics, 2007. CA: A Cancer Journal for Clinicians, 57(1), 43-66.
22. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., et al. (2006). Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New England Journal of Medicine, 354(24), 2542-2551.
23. Kantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., et al. (2007). Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood, 109(12), 5143-5150.
24. Kantarjian, H.M., Rousselot, P., Pasquini, R., Hamerschlak, N., Holowiecki, J., Dejardin, D., et al. (2007). Dasatinib or high-dose imatinib for patients with chronic-phase chronic myeloid leukemia resistant to standard-dose imatinib: 2-year follow-up data from START-R (CA180-017) [Abstract 736]. Blood (ASH Annual Meeting Abstracts), 110(11).
25. Lahaye, T., Riehm, B., Berger, U., Paschka, P., Müller, M.C., Kreil, S., et al. (2005). Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up. Cancer, 103(8), 1659-1669.
26. le Coutre, P., Ottmann, O.G., Giles, F., Kim, D.W., Cortes, J., Gattermann, N., et al. (2008). Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood, 111(4), 1834-1839.
27. Lionberger, J.M., Wilson, M.B., & Smithgall, T.E. (2000). Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. Journal of Biological Chemistry, 275(24), 18581-18585.
28. Meyn, M.A., III, Wilson, M.B., Abdi, F.A., Fahey, N., Schiavone, A.P., Wu, J., et al. (2006). Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. Journal of Biological Chemistry, 281(41), 30907-30916.
29. TM: Chronic myelogenous leukemia. Retrieved September 30, 2007, from http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf
30. ® prescribing information. Retrieved July 21, 2008, from http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf
31. O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., et al. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 348(11), 994-1004.
32. O'Hare, T., Walters, D.K., Stoffregen, E.P., Jia, T., Manley, P.W., Mestan, J., et al. (2005). In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Research, 65(11), 4500-4505.
33. Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of Medicine, 353(5), 487-497.
34. Ottmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., Larson, R.A., et al. (2007). Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: Interim results of a phase 2 study. Blood, 110(7), 2309-2315.
35. Papaioannou, A., Kennedy, C.C., Dolovich, L., Lau, E., & Adachi, J.D. (2007). Patient adherence to osteoporosis medications: Problems, consequences and management strategies. Drugs and Aging, 24(1), 37-55.
36. Partridge, A.H., Avorn, J., Wang, P.S., & Winer, E.P. (2002). Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute, 94(9), 652-661.
37. Porkka, K., Simonsson, B., Dombret, H., Martinelli, G., Ottman, O.G., Zhu, C., et al. (2007). Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-015) [Abstract 2810]. Blood (ASH Annual Meeting Abstracts), 110(11).
38. Ramirez, P., & DiPersio, J.F. (2008). Therapy options in imatinib failures. Oncologist, 13(4), 424-434.
39. Sawyers, C.L. (1999). Chronic myeloid leukemia. New England Journal of Medicine, 340(17), 1330-1340.
40. ®) vs escalated dose of imatinib (im) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib: Results of the CA180-017 START-R randomized study [Abstract 167]. Blood (ASH Annual Meeting Abstracts), 108(11).
41. Shah, N.P., Kim, D.W., Kantarjian, H.M., Rousselot, P., Dorlhiac-Llacer, P.E., Milone, J.H., et al. (2007). Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: One-year results of CA180034 [Abstract 7004]. Journal of Clinical Oncology (2007 ASCO Annual Meeting Proceedings Part I), 25(18S).
42. Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D., & Sawyers, C.L. (2004). Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 305(5682), 399-401.
43. Soverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F., Poerio, A., et al. (2006). Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clinical Cancer Research, 12(24), 7374-7379.
44. Soverini, S., Martinelli, G., Iacobucci, I., & Baccarani, M. (2008). Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Review of Anticancer Therapy, 8(6), 853-864.
45. Stone, R.M., Kantarjian, H.M., Baccarani, M., Lipton, J.H., Hughes, T., Ezzeddine, R., et al. (2007). Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013) [Abstract 734]. Blood (ASH Annual Meeting Abstracts), 110(11).
46. Sun, S.X., Fincher, C.L., Wang, J., Lee, K.Y., & Buchner, D. (2007). Real-world adherence rates of chronic myeloid leukemia patients to higher doses of imatinib. Journal of Managed Care Pharmacy, 13(8), 705-706.